The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators

Steroids

Volumn 90, Issue , 2014, Pages 3-12

  Craig Jordan, V ^a   McDaniel, Russell ^a   Agboke, Fadeke ^a   Maximov, Philipp Y ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast cancer; Endometrial cancer; Osteoporosis; Women's health

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN; METABOLISM;

ANIMALS; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84908668259     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2014.06.009     Document Type: Article

References (97)

1. L.J. Lerner, F.J. Holthaus Jr., and C.R. Thompson A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol Endocrinology 63 3 1958 Sep 295 318
2. R.B. Greenblatt, W.E. Barfield, E.C. Jungck, and A.W. Ray Induction of ovulation with MRL/41. Preliminary report JAMA 14 178 1961 Oct 101 104
3. L.J. Lerner The first nonsteroidal antioestrogen - MER25 R.L. Sutherland, V.C. Jordan, Non-steroidal antioestrogens: molecular pharmacology and antitumour activity 1981 Academic Press Sydney and New York 1 16
4. J. Avigan, D. Steinberg, H.E. Vroman, M.J. Thompson, and E. Mosettig Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29 J Biol Chem 235 1960 Nov 3123 3126
5. R.C. Laughlin, and T.F. Carey Cataracts in patients treated with triparanol JAMA 28 181 1962 Jul 339 340
6. C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada, and V. Raina Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 9869 2013 Mar 9 805 816
7. A.L. Herbst, C.T. Griffiths, and R.W. Kistner Clomiphene Citrate (NSC-35770) in disseminated mammary carcinoma Cancer Chemother Rep 43 1964 Dec 39 41
8. D. Lednicer, S.C. Lyster, B.D. Aspergren, and G.W. Duncan Mammalian antifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-aryl-2-phenyl-3,4-dihydronaphthalenes, and their derivatives J Med Chem 9 2 1966 Mar 172 176
9. S.S. Legha, M. Slavik, and S.K. Carter Nafoxidine - an antiestrogen for the treatment of breast cancer Cancer 38 4 1976 Oct 1535 1541
10. Consensus development conference Report: adjuvant chemotherapy of breast cancer JAMA 254 15 1985 Oct 18 3461 3463
11. R.N. Iyer, R. Gopalachari, V.P. Kamboj, and A.B. Kar Anti-implantation effect of 2,3-diphenylacrylophenones Indian J Exp Biol 5 3 1967 Jul 169 170
12. C.D. Jones, T. Suarez, E.H. Massey, L.J. Black, and F.C. Tinsley Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt J Med Chem 22 8 1979 Aug 962 966
13. L.J. Black, and R.L. Goode Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice Life Sci 26 17 1980 Apr 28 1453 1458
14. L.J. Black, C.D. Jones, and J.F. Falcone Antagonism of estrogen action with a new benzothiophene derived antiestrogen Life Sci 32 9 1983 Feb 28 1031 1036
15. V.C. Jordan, M.M. Collins, L. Rowsby, and G. Prestwich A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity J Endocrinol 75 2 1977 Nov 305 316
16. K.E. Allen, E.R. Clark, and V.C. Jordan Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships Br J Pharmacol 71 1 1980 83 91
17. A.P. Labhsetwar Role of oestrogen in spontaneous ovulation demonstrated by use of an antagonist of oestrogen, ICI 46,474 Nature 225 5227 1970 Jan 3 80 81
18. A.P. Labhsetwar Role of estrogens in ovulation: a study using the estrogen-antagonist, I.C.I. 46,474 Endocrinology 87 3 1970 Sep 542 551
19. A.P. Labhsetwar Effects of an antioestrogen on the corpus luteum of rabbits and rats J Reprod Fertil 25 2 1971 May 295 297
20. A.P. Labhsetwar Role of estrogens in spontaneous ovulation: evidence for the positive feedback in hamsters Endocrinology 90 4 1972 Apr 941 946
21. M.J. Harper, and A.L. Walpole Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes Nature 212 5057 1966 Oct 1 87
22. M.J. Harper, and A.L. Walpole A new derivative of triphenylethylene: effect on implantation and mode of action in rats J Reprod Fertil 13 1 1967 Feb 101 119
23. M.J. Harper, and A.L. Walpole Mode of action of I.C.I. 46,474 in preventing implantation in rats J Endocrinol 37 1 1967 Jan 83 92
24. V.C. Jordan The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole Breast Cancer Res Treat 11 3 1988 Jul 197 209
25. M.P. Cole, C.T. Jones, and I.D. Todd A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474 Br J Cancer 25 2 1971 Jun 270 275
26. H.W. Ward Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels Br Med J 1 5844 1973 Jan 6 13 14
27. A. Klopper, and M. Hall New synthetic agent for the induction of ovulation: preliminary trials in women Br Med J 1 5741 1971 Jan 16 152 154
28. V.C. Jordan, and S. Koerner Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor Eur J Cancer 11 3 1975 Mar 205 206
29. V.C. Jordan Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethyl benzanthracene (DMBA)-induced rat mammary carcinoma model J Steroid Biochem 5 1974 354
30. V.C. Jordan Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata Eur J Cancer 12 6 1976 Jun 419 424
31. Jordan VC. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endocr Relat Cancer 1978;(October supplement):49-55.
32. V.C. Jordan, and K.E. Allen Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model Eur J Cancer 16 2 1980 Feb 239 251
33. Jordan VC, Dix CJ, Allen KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon S, Jones S, editors. Adjuvant Therapy of Cancer II. New York: Grune & Stratton Inc; 1979. p. 19-26.
34. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 9114 1998 May 16 1451 1467
35. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 2005 May 14-20 1687 1717
36. C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, and S. Darby Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 9793 2011 Aug 27 771 784
37. A. Lacassagne Hormonal pathogenesis of adenocarcinoma of the breast Am J Cancer 27 2 1936 217 228
38. L.J. Lerner, and V.C. Jordan Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture Cancer Res 50 14 1990 Jul 15 4177 4189
39. R.F. Glascock, and W.G. Hoekstra Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep Biochem J 72 1959 Aug 673 682
40. E.V. Jensen, and H.I. Jacobson Basic guides to the mechanism of estrogen action Recent Prog Horm Res 18 1962 387 414
41. D. Toft, and J. Gorski A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization Proc Natl Acad Sci USA 55 6 1966 Jun 1574 1581
42. D. Toft, G. Shyamala, and J. Gorski A receptor molecule for estrogens: studies using a cell-free system Proc Natl Acad Sci USA 57 6 1967 Jun 1740 1743
43. McGuire WL, Carbone PP, Vollmer EP, editors. Estrogen Receptors in Human Breast Cancer, Raven Press; 1975.
44. E.V. Jensen, and V.C. Jordan The estrogen receptor: a model for molecular medicine Clin Cancer Res 9 6 2003 Jun 1980 1989
45. V.C. Jordan, K.E. Naylor, C.J. Dix, and G. Prestwich Anti-oestrogen action in experimental breast cancer Recent Results Cancer Res 71 1980 30 44
46. J. Cuzick, and M. Baum Tamoxifen and contralateral breast cancer Lancet 2 8449 1985 Aug 3 282
47. T.J. Powles, J.R. Hardy, S.E. Ashley, G.M. Farrington, D. Cosgrove, and J.B. Davey A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer Br J Cancer 60 1 1989 Jul 126 131
48. T.J. Powles, S. Ashley, A. Tidy, I.E. Smith, and M. Dowsett Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial J Natl Cancer Inst 99 4 2007 Feb 21 283 290
49. S.D. Lyman, and V.C. Jordan Metabolism of tamoxifen and its uterotrophic activity Biochem Pharmacol 34 15 1985 Aug 1 2787 2794
50. V.C. Jordan, and S.P. Robinson Species-specific pharmacology of antiestrogens: role of metabolism Fed Proc 46 5 1987 Apr 1870 1874
51. V.C. Jordan, M.K. Lababidi, and S. Langan-Fahey Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy J Natl Cancer Inst 83 7 1991 Apr 3 492 496
52. M.M. Gottardis, S.P. Robinson, P.G. Satyaswaroop, and V.C. Jordan Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse Cancer Res 48 4 1988 Feb 15 812 815
53. L. Hardell Tamoxifen as risk factor for carcinoma of corpus uteri Lancet 2 8610 1988 Sep 3 563
54. V.C. Jordan Tamoxifen and endometrial cancer Lancet 2 8618 1988 Oct 29 1019
55. T. Fornander, L.E. Rutqvist, B. Cedermark, U. Glas, A. Mattsson, and C. Silfversward Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet 1 8630 1989 Jan 21 117 120
56. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 7 1994 Apr 6 527 537
57. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, and W.M. Cronin Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 18 1998 Sep 16 1371 1388
58. T. Powles, R. Eeles, S. Ashley, D. Easton, J. Chang, and M. Dowsett Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Lancet 352 9122 1998 Jul 11 98 101
59. J. Cuzick, J. Forbes, R. Edwards, M. Baum, S. Cawthorn, and A. Coates First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial Lancet 360 9336 2002 Sep 14 817 824
60. G.M. Williams, M.J. Iatropoulos, M.V. Djordjevic, and O.P. Kaltenberg The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat Carcinogenesis 14 2 1993 Feb 315 317
61. P. Greaves, R. Goonetilleke, G. Nunn, J. Topham, and T. Orton Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats Cancer Res 53 17 1993 Sep 1 3919 3924
62. G.C. Hard, M.J. Iatropoulos, K. Jordan, L. Radi, O.P. Kaltenberg, and A.R. Imondi Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats Cancer Res 53 19 1993 Oct 1 4534 4541
63. V.C. Jordan What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective Ann Oncol 6 1 1995 Jan 29 34
64. B. Fisher, J.P. Costantino, D.L. Wickerham, R.S. Cecchini, W.M. Cronin, and A. Robidoux Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 22 2005 Nov 16 1652 1662
65. J. Cuzick, J.F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, and K. Holli Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial J Natl Cancer Inst 99 4 2007 Feb 21 272 282
66. Jordan C. Tamoxifen as the first targeted long term adjuvant therapy for breast cancer. Endocr Relat Cancer 2014 Mar 21.
67. V.C. Jordan, E. Phelps, and J.U. Lindgren Effects of anti-estrogens on bone in castrated and intact female rats Breast Cancer Res Treat 10 1 1987 Oct 31 35
68. R.R. Love, P.A. Newcomb, D.A. Wiebe, T.S. Surawicz, V.C. Jordan, and P.P. Carbone Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer J Natl Cancer Inst 82 16 1990 Aug 15 1327 1332
69. R.R. Love, D.A. Wiebe, P.A. Newcomb, L. Cameron, H. Leventhal, and V.C. Jordan Effects of tamoxifen on cardiovascular risk factors in postmenopausal women Ann Intern Med 115 11 1991 Dec 1 860 864
70. R.R. Love, R.B. Mazess, H.S. Barden, S. Epstein, P.A. Newcomb, and V.C. Jordan Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N Engl J Med 326 13 1992 Mar 26 852 856
71. V.C. Jordan Tamoxifen: a most unlikely pioneering medicine Nat Rev Drug Discov 2 3 2003 Mar 205 213
72. M.M. Gottardis, and V.C. Jordan Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model Cancer Res 47 15 1987 Aug 1 4020 4024
73. V.C. Jordan, and B. Gosden Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor J Steroid Biochem 19 3 1983 Sep 1249 1258
74. V.C. Jordan, and B. Gosden Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018 Endocrinology 113 2 1983 Aug 463 468
75. M.M. Gottardis, M.E. Ricchio, P.G. Satyaswaroop, and V.C. Jordan Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice Cancer Res 50 11 1990 Jun 1 3189 3192
76. L.J. Black, M. Sato, E.R. Rowley, D.E. Magee, A. Bekele, and D.C. Williams Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats J Clin Invest 93 1 1994 Jan 63 69
77. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, and J.A. Cauley The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 23 1999 Jun 16 2189 2197
78. S. Martino, J.A. Cauley, E. Barrett-Connor, T.J. Powles, J. Mershon, and D. Disch Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 23 2004 Dec 1 1751 1761
79. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 23 2006 Jun 21 2727 2741
80. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, and J.N. Atkins Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer Cancer Prev Res 3 6 2010 Jun 696 706
81. V.C. Jordan Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations Cancer Invest 6 5 1988 589 595
82. L.R. Wiseman, and K.L. Goa Toremifene. a review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer Drugs 54 1 1997 Jul 141 160
83. P.Y. Maximov, T.M. Lee, and V.C. Jordan The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice Curr Clin Pharmacol 8 2 2013 May 135 155
84. Jordan VC. A(nother) scientific strategy to prevent breast cancer in post-menopausal women by enhancing estrogen-induced apoptosis?. Menopause [ePub].
85. S.P. Robinson, R. Koch, and V.C. Jordan In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo Cancer Res 48 4 1988 Feb 15 784 787
86. C.P. Miller, M.D. Collini, B.D. Tran, H.A. Harris, Y.P. Kharode, and J.T. Marzolf Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens J Med Chem 44 11 2001 May 24 1654 1657
87. R.R. Bain, and V.C. Jordan Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy Biochem Pharmacol 32 2 1983 Jan 15 373 375
88. V.C. Jordan, R.R. Bain, R.R. Brown, B. Gosden, and M.A. Santos Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer Cancer Res 43 3 1983 Mar 1446 1450
89. S.R. Cummings, K. Ensrud, P.D. Delmas, A.Z. LaCroix, S. Vukicevic, and D.M. Reid Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 8 2010 Feb 25 686 696
90. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 7 1999 Aug 18 637 645
91. E. Barrett-Connor, L. Mosca, P. Collins, M.J. Geiger, D. Grady, and M. Kornitzer Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2 2006 Jul 13 125 137
92. Jordan VC. Repurposing failed pharmaceuticals as the first targeted medicines for the treatment and prevention of breast cancer. Hamdan Med J. in press.
93. A.Z. LaCroix, T. Powles, C.K. Osborne, K. Wolter, J.R. Thompson, and D.D. Thompson Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women J Natl Cancer Inst 102 22 2010 Nov 17 1706 1715
94. M.M. Gottardis, S.Y. Jiang, M.H. Jeng, and V.C. Jordan Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens Cancer Res 49 15 1989 Aug 1 4090 4093
95. P.Y. Maximov, R.E. McDaniel, and V.C. Jordan Tamoxifen: pioneering medicine in breast cancer. Milestones in drug therapy 2013 Springer Basel
96. V.C. Jordan Estrogen action, selective estrogen receptor modulators and women's health: progress and promise 2013 Imperial College Press London
97. J.S. Lewis, and V.C. Jordan Case histories: raloxifene J. Taylor, D. Triggle, Comprehensive medicinal chemistry II 2006 Elsevier Limited Oxford 103 121